Medtronic (MDT) Releases FY19 Earnings Guidance

Medtronic (NYSE:MDT) updated its FY19 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $5.14-5.16 for the period, compared to the Thomson Reuters consensus estimate of $5.12.

A number of equities analysts have issued reports on the company. Needham & Company LLC reiterated a strong-buy rating and set a $117.00 price target (down previously from $120.00) on shares of Medtronic in a research note on Monday, February 4th. Credit Suisse Group assumed coverage on Medtronic in a research note on Monday, December 17th. They set an outperform rating and a $109.00 price target for the company. UBS Group assumed coverage on Medtronic in a research note on Wednesday, November 28th. They set a buy rating and a $112.00 price target for the company. Raymond James cut their price target on Medtronic from $105.00 to $104.00 and set an outperform rating for the company in a research note on Wednesday, November 21st. Finally, Morgan Stanley boosted their target price on Medtronic from $98.00 to $102.00 and gave the stock an equal weight rating in a research note on Wednesday, January 2nd. Nine research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of Buy and an average price target of $104.09.

Shares of NYSE MDT opened at $92.27 on Tuesday. Medtronic has a twelve month low of $76.41 and a twelve month high of $100.15. The company has a market capitalization of $123.92 billion, a PE ratio of 19.34, a price-to-earnings-growth ratio of 2.41 and a beta of 0.82. The company has a current ratio of 2.56, a quick ratio of 2.11 and a debt-to-equity ratio of 0.48.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, November 20th. The medical technology company reported $1.22 earnings per share for the quarter, topping analysts’ consensus estimates of $1.15 by $0.07. The firm had revenue of $7.48 billion for the quarter, compared to the consensus estimate of $7.35 billion. Medtronic had a return on equity of 13.51% and a net margin of 7.44%. The company’s revenue was up 6.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.07 EPS. On average, analysts forecast that Medtronic will post 5.13 EPS for the current fiscal year.

In related news, CEO Omar Ishrak purchased 12,000 shares of the stock in a transaction that occurred on Wednesday, January 9th. The shares were bought at an average price of $84.05 per share, with a total value of $1,008,600.00. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Karen L. Parkhill purchased 3,000 shares of the stock in a transaction that occurred on Wednesday, January 9th. The stock was bought at an average cost of $83.87 per share, for a total transaction of $251,610.00. The disclosure for this purchase can be found here. Insiders own 0.28% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was first published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.thelincolnianonline.com/2019/02/19/medtronic-mdt-releases-fy19-earnings-guidance.html.

About Medtronic

Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group.

Featured Article: Is the QQQ ETF safe?

Earnings History and Estimates for Medtronic (NYSE:MDT)

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.